In patients with virologic failure on a tenofovir-containing regimen, tenofovir resistance was highest in sub-Saharan Africa, reaching 57%.
Tenofovir-containing regimens are now recommended as first-line therapy for HIV patients as well as for prophylaxis. However, data are limited regarding prevalence of acquired tenofovir resistance.
To assess HIV drug resistance worldwide, investigators conducted a retrospective cohort study involving 1926 HIV patients from 36 countries who were diagnosed with treatment failure between 1998 and 2015. Patients were receiving a first-line regimen containing tenofovir plus a nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI; lamivudine or emtricitabine) plus a non-NRTI (efavirenz or nevirapine).
The prevalence of tenofovir resistance, as determined by the presence of K65R/N or K70E/G/Q RT gene mutations, ranged from 20% in Europe to 57%…
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes